[go: up one dir, main page]

MA33675B1 - Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1 - Google Patents

Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1

Info

Publication number
MA33675B1
MA33675B1 MA34779A MA34779A MA33675B1 MA 33675 B1 MA33675 B1 MA 33675B1 MA 34779 A MA34779 A MA 34779A MA 34779 A MA34779 A MA 34779A MA 33675 B1 MA33675 B1 MA 33675B1
Authority
MA
Morocco
Prior art keywords
receptor antagonists
pyrazolobidine
indazole
compound
ccr1 receptor
Prior art date
Application number
MA34779A
Other languages
Arabic (ar)
English (en)
Inventor
Can Mao
Hossein Razavi
Brian Nicholas Cook
Daniel Kuzmich
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43126891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33675B1 publication Critical patent/MA33675B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR DES ANTAGONISTES DU RÉCEPTEUR CCR1 REPRÉSENTÉ PAR LA FORMULE (I) (FORMULE (I)) DANS LAQUELLE X REPRÉSENTE L'AZOTE OU C-R2; AR1 REPRÉSENTE UN CARBOCYCLE, UN HÉTÉROARYLE OU UN HÉTÉROCYCLYLE CHACUN ÉVENTUELLEMENT SUBSTITUÉ PAR UN À TROIS RA ; AR2 REPRÉSENTE UN CARBOCYCLE, UN HÉTÉROARYLE OU UN HÉTÉROCYCLYLE CHACUN ÉVENTUELLEMENT SUBSTITUÉ PAR UN À TROIS RB; G CYCLIQUE REPRÉSENTE UN CARBOCYCLE OU UN HÉTÉROCYCLYLE CHACUN ÉVENTUELLEMENT SUBSTITUÉ PAR UN À DEUX R8; R1 REPRÉSENTE HYDROGÈNE, ALKYLE EN C1-6 OU (ALCOXY EN C1-6)(ALKYLE EN C1-6). L'INVENTION PORTE ÉGALEMENT SUR DES COMPOSITIONS, SUR DES PROCÉDÉS DE FABRICATION ET D'UTILISATION DE COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I).
MA34779A 2009-10-21 2012-04-16 Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1 MA33675B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25359009P 2009-10-21 2009-10-21
PCT/US2010/053142 WO2011049917A1 (fr) 2009-10-21 2010-10-19 Composés d'indazole et de pyrazolopyridine comme antagonistes du récepteur ccr1

Publications (1)

Publication Number Publication Date
MA33675B1 true MA33675B1 (fr) 2012-10-01

Family

ID=43126891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34779A MA33675B1 (fr) 2009-10-21 2012-04-16 Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1

Country Status (30)

Country Link
US (1) US9056858B2 (fr)
EP (1) EP2491028B1 (fr)
JP (1) JP5542946B2 (fr)
KR (1) KR20120087923A (fr)
CN (1) CN102666526A (fr)
AP (1) AP2012006204A0 (fr)
AU (1) AU2010308277A1 (fr)
BR (1) BR112012009331A2 (fr)
CA (1) CA2778060A1 (fr)
CL (1) CL2012000967A1 (fr)
CO (1) CO6531488A2 (fr)
DK (1) DK2491028T3 (fr)
EA (1) EA021015B1 (fr)
EC (1) ECSP12011904A (fr)
ES (1) ES2444780T3 (fr)
GE (1) GEP20146103B (fr)
HR (1) HRP20140213T1 (fr)
IL (1) IL218823A0 (fr)
IN (1) IN2012DN03449A (fr)
MA (1) MA33675B1 (fr)
MX (1) MX2012004644A (fr)
NZ (1) NZ599132A (fr)
PE (1) PE20121433A1 (fr)
PH (1) PH12012500775A1 (fr)
PL (1) PL2491028T3 (fr)
PT (1) PT2491028E (fr)
RS (1) RS53130B (fr)
SI (1) SI2491028T1 (fr)
TN (1) TN2012000180A1 (fr)
WO (1) WO2011049917A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285783B1 (fr) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Composés indazole comme antagonistes des récepteurs ccr1
CA2722811C (fr) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Composes de pyrazole comme antagonistes de ccr1
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
WO2011056440A1 (fr) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
WO2013060865A1 (fr) 2011-10-28 2013-05-02 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci
EP3131902B1 (fr) 2014-04-14 2019-06-12 Boehringer Ingelheim International GmbH Composés utilisés comme modulateurs de ror gamma
CN112707831A (zh) * 2021-02-05 2021-04-27 阿里生物新材料（常州）有限公司 一种3-（1-氨基环丙基）苯甲酸甲酯的合成方法
WO2025248032A1 (fr) 2024-05-31 2025-12-04 Syngenta Crop Protection Ag Composés d'indazole à action pesticide

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338625C (fr) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Composes tricycliques
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
DE69232907T2 (de) 1991-03-28 2003-05-15 Eisai Co., Ltd. Neue heterocyclische/cyclische amine
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
EP0606489A4 (fr) 1992-07-03 1995-01-25 Kumiai Chemical Industry Co Derive heterocyclique condense et desherbant.
BR9405488A (pt) 1993-06-25 1999-06-01 Kumiai Chemical Industry Co Derivado de indazolsulfoniluréia seu uso e intermediário para sua produção
EP0796258A1 (fr) 1994-12-06 1997-09-24 MERCK SHARP & DOHME LTD. Derives de l'azetidine, de la pyrrolidine et de la piperidine utilises comme agonistes des recepteurs 5-ht1
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
AU1345697A (en) 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
AU754184B2 (en) 1997-11-04 2002-11-07 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
WO2000076970A2 (fr) 1999-06-14 2000-12-21 Eli Lilly And Company Composes
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
WO2001000656A2 (fr) 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Indazole peptidomimetiques utilises comme antagonistes recepteurs de thrombine
WO2001065218A1 (fr) 2000-03-02 2001-09-07 Ndc Infrared Engineering Limited Dispositif de detection electromagnetique
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
CA2478232C (fr) 2002-04-11 2011-06-14 Boehringer Ingelheim Pharmaceuticals, Inc. Derives d'amides heterocycliques utilises en tant qu'inhibiteurs de cytokine
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
ATE438401T1 (de) 2002-06-12 2009-08-15 Chemocentryx Inc 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
CA2494942A1 (fr) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Composes benzimidazole substitues
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
ATE423122T1 (de) 2003-08-15 2009-03-15 Astrazeneca Ab Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
WO2006091496A2 (fr) 2005-02-24 2006-08-31 Merck & Co., Inc. Potentialisateurs de benzazole de recepteurs de glutamate metabotropique
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CA2960117C (fr) 2005-05-17 2018-01-30 Sarcode Bioscience Inc. Antagonistes de lfa-1 destines au traitement de troubles de l'oeil
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP5275794B2 (ja) 2005-06-22 2013-08-28 ケモセントリックス，インコーポレイティド アザインダゾール化合物および使用方法
WO2007028083A2 (fr) 2005-09-01 2007-03-08 Eli Lilly And Company Utilisation de 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines comme agonistes des recepteurs 5-ht2c
EP1940394A4 (fr) 2005-10-25 2009-07-08 Smithkline Beecham Corp Composés chimiques
JP2009544616A (ja) 2006-07-21 2009-12-17 武田薬品工業株式会社 アミド化合物
JP5491199B2 (ja) 2007-01-19 2014-05-14 アルデア バイオサイエンシズ，インコーポレイティド Ｍｅｋのインヒビター
KR20100039862A (ko) 2007-06-26 2010-04-16 아스트라제네카 아베 카텝신 ｋ 억제제로서 1-시아노사이클로프로필-유도체
US20110028507A1 (en) 2007-08-10 2011-02-03 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
DK2225238T3 (en) 2007-11-29 2014-11-24 Boehringer Ingelheim Int Derivatives of 6,7-dihydro-5H-imidazoý1,2- imidazol-3-carboxylic acid amides.
EP2285783B1 (fr) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Composés indazole comme antagonistes des récepteurs ccr1
CA2722811C (fr) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Composes de pyrazole comme antagonistes de ccr1
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
WO2011056440A1 (fr) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
EP2509952A1 (fr) 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Procédé de synthèse d'intermédiaires utiles pour la fabrication de for composés à substitution indazole et aza-indazole
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物

Also Published As

Publication number Publication date
KR20120087923A (ko) 2012-08-07
PH12012500775A1 (en) 2012-11-26
GEP20146103B (en) 2014-05-27
EP2491028B1 (fr) 2013-12-11
PL2491028T3 (pl) 2014-05-30
US20120270870A1 (en) 2012-10-25
CA2778060A1 (fr) 2011-04-28
ECSP12011904A (es) 2012-10-30
PE20121433A1 (es) 2012-11-10
EP2491028A1 (fr) 2012-08-29
IL218823A0 (en) 2012-06-28
CL2012000967A1 (es) 2012-09-14
WO2011049917A1 (fr) 2011-04-28
SI2491028T1 (sl) 2014-03-31
IN2012DN03449A (fr) 2015-10-23
NZ599132A (en) 2014-05-30
BR112012009331A2 (pt) 2019-09-24
ES2444780T3 (es) 2014-02-26
AU2010308277A1 (en) 2012-04-26
HRP20140213T1 (hr) 2014-04-11
MX2012004644A (es) 2012-05-08
PT2491028E (pt) 2014-02-04
AP2012006204A0 (en) 2012-04-30
EA201200602A1 (ru) 2012-12-28
EA021015B1 (ru) 2015-03-31
RS53130B (sr) 2014-06-30
CO6531488A2 (es) 2012-09-28
US9056858B2 (en) 2015-06-16
TN2012000180A1 (en) 2013-12-12
JP2013508376A (ja) 2013-03-07
DK2491028T3 (da) 2014-01-13
CN102666526A (zh) 2012-09-12
JP5542946B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
MA33675B1 (fr) Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1
PH12014500852A1 (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
ATE483707T1 (de) 2-cyclopropylthiazolderivate
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
CL2009000127A1 (es) Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1.
MX2015013348A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
MX340572B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
MX2009013262A (es) Derivados de heterociclil-pirimidinil-amino fungicidas.
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MX2009010505A (es) Derivados de piridina y pirimidina como antagonistas de mglur2.
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
WO2013177534A3 (fr) Nouveaux dérivés d'acide salicylique, sel de qualité pharmaceutique correspondant, composition et procédé d'utilisation correspondants
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MX2009008028A (es) Agentes antiparasitarios.
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines